FGF Receptor 4 (D3B12) XP ® Rabbit mAb 8562S from Cell Signaling Technology

Product Specs
ItemFGF Receptor 4 (D3B12) XP ® Rabbit mAb
CompanyCell Signaling Technology
Price $371.00 Inquire
Catalog Number8562S
Quantity100 µl
ApplicationsW, IP, IF-IC
ReactivityH
TargetFGFR4
HostRabbit
NCBI Gene AliasesCD334, JTK2, TKF
ClonalityMonoclonal
NCBI Full Gene Namefibroblast growth factor receptor 4
Research AreaRTK
IsotypeIgG
CloneD3B12
Molecular Weight95, 125

Questions and Answers

What role does FGF Receptor 4 play in cancer biology, and how might this antibody be useful in my research?

FGF Receptor 4 has been implicated in various cancers, including rhabdomyosarcomas and non-small cell lung cancer. For instance, aberrant expression of FGFR4 has been linked to tumor progression and poor prognosis in lung cancer, as it induces pro-oncogenic signaling pathways such as MAPK and STAT3 activation, which are associated with epithelial-mesenchymal transition and tumor survival mechanisms (; ). This antibody can be utilized to study FGFR4 expression and its downstream effects in these contexts.

Can this antibody be used to investigate the mechanisms of drug resistance in cancer cells?

Yes, the FGF Receptor 4 antibody can be instrumental in studying drug resistance mechanisms. For example, research has shown that FGFR4 signaling contributes to the adaptive survival of cancer cells under therapeutic stress, such as in hepatocellular carcinoma where FGFR4-ERK signaling is involved in overcoming resistance to sorafenib (). This antibody can help elucidate the role of FGFR4 in mediating such resistance.

Is there evidence of FGF Receptor 4's involvement in non-cell autonomous signaling in cancer?

Yes, FGF Receptor 4 is involved in non-cell autonomous signaling, particularly in the context of apoptotic stress. Research indicates that cells undergoing apoptosis can secrete FGF2, which activates FGFR signaling in neighboring cells, leading to the upregulation of pro-survival proteins like BCL-2, thereby promoting resistance to cell death in surrounding cells (). This antibody could be used to explore these interactions further.

How does FGFR4 expression correlate with patient outcomes in cancer?

FGFR4 expression has been correlated with poor overall survival and progression-free survival in various cancers, including gastric cancer. Studies have shown that high levels of FGFR4 are associated with increased tumor proliferation and invasion, making it a potential prognostic biomarker (). Utilizing this antibody could aid in assessing FGFR4 levels in clinical samples to evaluate its prognostic significance.

Cell Signaling Technology

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

Company Profile

Website: http://www.cellsignal.com/

Website: Technical Support

(1) FGF23 Controls Myocardial Fibrosis Progression via Promoting Cardiac Fibroblast Proliferation and Activation in MiceBiology (Basel)March 27, 2026Leyi Shen, Mingqi Hu, Mei Xue, Santie LiAntibodies used in this study were FGF23 (#ab307420, 1:1000 dilution; Abcam, Cambridge, MA, USA), FGFR4 (#8562, 1:1000 dilution; Cell Signaling Technology, Danvers, MA, USA), α-SMA (#19245, 1:2000 dilution; Cell

(2) Mechanistic study of glutamine metabolic reprogramming driving non-small cell lung cancer progression via the FGF17-FGFR4 axis mediating epithelial-mesenchymal transitionFrontiers in Molecular BiosciencesJanuary 2, 2026Qinghua Kong, Xiaoyan Wang, Wei Ding(1:2000; #5741, CST), GLUL (1:1000; #80636, CST), FGF17 (1:1000; PA5-109722, Thermo), FGFR4 (1:1500; #8562, CST), MEK5 (1:1500; #40473, CST)、phospho-MEK5 (Thr) (1:1000; PA5-105899, Thermo), ERK5 (1:1500; #12950,

(3) Involvement of the FGF8 and Fibroblast Growth Factor Receptor signaling pathway in the maintenance and progression of fusion-positive rhabdomyosarcomaMolecular Cancer TherapeuticsDecember 15, 2025Salah Boudjadi, Hana Kim, Bishwanath Chatterjee, Pawan Kumar Raut, Thanh Hung. Nguyen, Puspa Raj Pandey, Reyaz ur ur Rasool, Wenyue Sun, Frederic G. BarrCell Signaling Technology Cat# 4574) (RRID:AB_2246903), FGFR4 (1:1000, Cell Signaling Technology Cat# 8562) (RRID:AB_10891199), FGF8 (1:1000, #16124, Sino Biological, Wayne, PA), pan-phosphotyrosine (Thermo Fisher Scientific

(4) Loss of lung mesenchymal identities in culture and a screening approach to identify restorative cuesAmerican Journal of Physiology-Lung Cellular and Molecular PhysiologyDecember 1, 2025Ana M. Diaz Diaz Espinosa, Jack H. Wellmerling, Natalia Del Pilar Del Pilar Vanegas, Jhonny Rodriguez-Lopez, Kyoung M. Choi, Nichole A. Schussler, Patrick A. Link, Luis R. Rodriguez, Grant Barringer, Mauricio Rojas, et al.,R&D Systems,MAB6194(AB_10890767),CBLP0223104,1.00,No,1.0010.00*15.0025.00,No FGFR4,R&D Systems,MAB6852-SP(AB_2231697),KHY0324041,0.50,Yes,25.00,No FGFR4,Cell Signaling,8562T(AB_10891199),5,-,-,1.50,No LIMCH1,Invitrogen,PA5-34745(AB_2552097),2H444060813,3.06,Yes,15.30,Yes CCBE1,Invitrogen,PA5-59534(AB_2639342),ZF4360275A,0.20,No,10.00,No CD82,Novus,NBP1-76775(AB_11010566),4073-0701,2.00,Yes,20.00,No CD82,Novus,NBP3-16797(AB_3599915),4000001501,-,-,5.30,No CD82,Miltenyi Biotec

(5) PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA -Mutated Solid Tumors and in Preclinical ModelsClinical Cancer ResearchNovember 20, 2025Dejan Juric, Kyung Song, Radia M. Johnson, Melissa K. Accordino, Philippe L. Bedard, Andrés Cervantes, Valentina Gambardella, Erika Hamilton, Antoine Italiano, Kevin Kalinsky, et al.FGFR2 (cat. No. 11835, RRID: AB_2797742), FGFR3 (cat. No. 4574, RRID: AB_2246903), FGFR4 (cat. No. 8562, RRID: AB_10891199), pFGFR Y653/654 (cat. No. 3476, RRID: AB_331369), and pFRS2A Y196 (cat. No. 3864,

(6) Isoliquiritigenin inhibits colorectal cancer progression by targeting the FGFR4/FASN mediated lipid metabolism pathwayJournal of CancerSeptember 25, 2025Xiaohui Zhai, Huizhi Yang, Zhiqin Tan, Song Wu, Qing Bao, Jian Liang, Hailin Tangantibodies overnight at 4°C36, 37. The primary antibodies used include GAPDH (#2118, 1:1000), FGFR4 (#8562, 1:1000), FASN (#3180, 1:1000), Phospho-Akt (Ser473) (#4060, 1:2000), PI3 Kinase p85 (#4292, 1:1000),

(7) FGF15/FGFR4 signaling suppresses M1 macrophage polarization and multi-organ inflammation in septic mice by inhibiting H3K18 lactylation-driven Irf7 expression through NF2-Hippo activationCell death & diseaseAugust 19, 2025Li B, Li J, Zhu Z, Tang Y, Zhou Y, Du G, Li X.interaction between FGFR4 and NF2, the cell lysates were incubated with anti-FGFR4 antibody (1:50; 8562S, CST, Danvers, MA, USA) or IgG (B900610, Proteintech) overnight at 4 °C, followed by Protein A/G agarose

(8) The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancerPLoS OneAugust 11, 2025Angela Abdollahi, Margaret Favata, Michael Weber, Valerie Roman, Rodrigo Hess, Kayla Hammond, Matthew R. Farren, Mike Schaffer, Aidan Gilmartin, Hui Wang, et al.otherwise noted: β-actin (1:5000 dilution, #5125), E-cadherin (#3195), ERK (#4695), FGFR1 (#9740S), FGFR4 (#8562S), FRS2a (#94826), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:2000 dilution, #5174S), pFRS2

(9) FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative roleBreast Cancer Research and TreatmentJune 1, 2025Kai Ding, Lyuqin Chen, Kevin M. Levine, Matthew J. Sikora, Nilgun Tasdemir, David Dabbs, Rachel Jankowitz, Rachel Hazan, Osama Shah, Jenny Atkinson, et al.antibody at 4 degree overnight. Primary antibody information is listed below: FGFR4 (Cell Signaling #8562, 1:1,000), ER-Alpha (Abcam #131105, 1:1,000), pFGFR4(Y642) (signalway #11836–2, 1:1,000), pFRS2(Y196)

(10) Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4J Biomed SciMarch 17, 2025Zhangyuan Gu, Fugui Ye, Hong Luo, Xiaoguang Li, Yue Gong, Shiqi Mao, Xiaoqing Jia, Xiangchen Han, Boyue Han, Yun Fu, et al.Cell Signaling Technology, catalog No. 5335), anti-FGFR4 (1:1000, Cell Signaling Technology, catalog No. 8562), anti-JAK1 (1:1000, Cell Signaling Technology, catalog No. 3344), anti-phospho-STAT3 (Tyr705) (1:1000,

(11) Integrative Multi‐Omics Approaches Reveal Selectivity Profiles and Molecular Mechanisms of FIIN‐2, a Covalent FGFR InhibitorAdvanced ScienceFebruary 20, 2025Ying Fu, Dandan Zhu, Xiaojuan Chen, Lingzhi Qu, Ming Guo, Shuhong Zhang, Guangyu Xu, Zhuchu Chen, Maoyu Li, Yongheng Chen4 °C. The primary antibodies used in this study were as follows: FGFR4 (Cell Signaling Technology, 8562), pFGFR (Tyr653/654) (Cell Signaling Technology, 3476), MAPK (Cell Signaling Technology, 9107), pMAPK

(12) BEACH domain proteins function as cargo-sorting adaptors in secretory and endocytic pathwaysThe Journal of cell biologyDecember 2, 2024Pankiv S, Dahl AK, Aas A, Andersen RL, Brech A, Holland P, Singh S, Bindesbøll C, Simonsen A.,Cell Signaling Technology,Cat# 45568 FGFR4 monoclonal (clone D3B12) antibody,Cell signaling Technology,Cat# 8562S EFNB2 monoclonal (clone JM53-21) antibody,Thermo Fisher Scientific,Cat# MA5-32740 EGFR antibody,Fitzgerald Industries

(13) FGF receptors mediate cellular senescence in the cystic fibrosis airway epitheliumJCI insightJune 25, 2024Easter M, Hirsch MJ, Harris E, Howze PH 4th, Matthews EL, Jones LI, Bollenbecker S, Vang S, Tyrrell DJ, Sanders YY, et al.antibodies: rabbit anti-p21 (catalog 29478), rabbit anti–BCL-xL (catalog 2764S), rabbit anti-FGFR4 (catalog 8562S), rabbit total and phospho–anti-ERK1/2 (catalog 4695S and 9101S), rabbit total and phospho–anti-p38

(14) FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugsCellular & Molecular Biology LettersMay 14, 2024Monika Gorska-Arcisz, Marta Popeda, Marcin Braun, Dominika Piasecka, Joanna I. Nowak, Kamila Kitowska, Grzegorz Stasilojc, Marcin Okroj, Hanna M. Romanska, Rafal Sadejanti-phospho-AMPKα Thr172 (#2535), anti-FGFR1 (#9740), anti-FGFR2 (#23328), anti-FGFR3 (#4574), anti-FGFR4 (#8562), anti-Lamin B1 (#13435), anti-LC3B (#2775), anti-mTOR (#2983), anti-phospho-mTOR Ser2448 (#5536), anti-SQSTM1/p62

(15) FGF18 alleviates hepatic ischemia-reperfusion injury via the USP16-mediated KEAP1/Nrf2 signaling pathway in male miceNature communicationsSeptember 30, 2023Tong G, Chen Y, Chen X, Fan J, Zhu K, Hu Z, Li S, Zhu J, Feng J, Wu Z, et al.1:1000), FGFR1 (CST, 9740S, 1:1000), FGFR2 (CST, 23328S, 1:1000), FGFR3 (CST, 4574S, 1:1000), FGFR4 (CST, 8562S, 1:1000), BCL-2 (Huabio, ET1702-53, 1:1000), BAX (CST 2772S, 1:1000), c-Cas-3 (CST, 9661S, 1:1000),

(16) Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric RhabdomyosarcomaCancersAugust 9, 2023Wu JT, Cheuk A, Isanogle K, Robinson C, Zhang X, Ceribelli M, Beck E, Shinn P, Klumpp-Thomas C, Wilson KM, et al.(Amersham, UK). The following antibodies were used: pFGFR4 (ab192589, Abcam, Cambridge, UK), FGFR4 (8562, Cell Signaling Technology (CST), Danvers, MA, USA), pERK1/2 (4370, CST), ERK1/2 (4695, CST), and GAPDH

(17) Structural basis for FGF hormone signallingNatureJune 1, 2023Chen L, Fu L, Sun J, Huang Z, Fang M, Zinkle A, Liu X, Lu J, Pan Z, Wang Y, et al.23328S, Cell Signaling Technology), total-FGFR3 (1:1000, no. ab133644, Abcam), total-FGFR4 (1:1000, no. 8562S, Cell Signaling Technology), HRP conjugated goat anti-mouse IgG (H + L) (1:5000, no. SA00001-1, Proteintech),

(18) 18F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imagingFrontiers in OncologyApril 27, 2023Yang Chen, Jingya Han, Yan Zhao, Xinming Zhao, Mengmeng Zhao, Jingmian Zhang, Jianfang Wangpurchased from Cell Signaling Technology, Inc. (CST, USA) with catalog numbers 9740S, 23328S, 4574S and 8562S. The FGFR1-4 primary antibodies were diluted to 1:1000, and GAPDH was diluted to 1:10000 with blocking

(19) GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion-positive rhabdomyosarcomaJCI insightDecember 8, 2022Morales J, Allegakoen DV, Garcia JA, Kwong K, Sahu PK, Fajardo DA, Pan Y, Horlbeck MA, Weissman JS, Gustafson WC, et al.(p)-AKT Ser473 (4060); EIF4E (2067); EIF4G (2469); EIF4E (2067); ERK (4695); (p)-ERK (4370); FGFR4 (8562); FOXO1 (2880); HA (3724); P70S6K (2708); (p)-p70S6K (9205); (p)-p90RSK Thr359/Ser363 (9344); MTOR (2983);

(20) FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinomaProceedings of the National Academy of Sciences of the United States of AmericaOctober 4, 2022Tao Z, Cui Y, Xu X, Han T.1:1,000), anti-FGFR3 (Cell Signaling Technology, 4574; 1:1,000), anti-FGFR4 (Cell Signaling Technology, 8562; 1:5,000), anti-FGF19 (ABclonal, A6589; 1:2,000), anti-KLB (R&D Systems, MAB5889; 1:1,000), anti-PARP1

Be the First to Write a Review!

FGF Receptor 4 (D3B12) XP ® Rabbit mAb

FGF Receptor 4 (D3B12) XP ® Rabbit mAb from Cell Signaling Technology

Description

Questions and Answers

Cell Signaling Technology

Citations (44)

Reviews

FGF Receptor 4 (D3B12) XP ® Rabbit mAb from Cell Signaling Technology

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map